The European Medicines Agency (EMA) could soon change the face of cancer treatment with its potential approval of two novel bispecific antibodies, epcoritamab and talquetamab. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting conditional marketing authorization for two novel cancer therapies — AbbVie’s epcoritamab and Janssen’s talquetamab. Epcoritamab for relapsed/refractory…
iBio’s chief reveals strategy behind AI-driven bispecific antibody discovery plans
Biotech firm iBio (NYSEA:IBIO) has incorporated EngageTx, a machine learning-driven technology, into its development roadmap. This T-cell engaging antibody panel assists in generating bispecific antibodies targeting cancer cells. In particular, the firm is developing a novel Trophoblast Cell Surface Antigen 2 (TROP-2) bispecific molecule to target TROP-2-positive cancers. In addition to their focus on oncology,…